广州慧智微电子股份有限公司发布了关于2021年股票期权激励计划第二个行权期第一次行权结果暨股份 变动的公告。主要内容包括：- 本次行权股票数量为6,081,000份，行权股票自行权日起满三年可上市流 通，预计上市流通时间为2028年7月25日。- 本次行权人数共51人，行权股票来源于公司向激励对象定 向发行的A股普通股股票。- 行权后，公司总股本将由460,762,548股变更为466,843,548股。- 天健会计师 事务所出具验资报告，确认截至2025年7月9日，公司收到行权出资款合计人民币6,945,000.00元，其中 增加股本人民币6,081,000.00元，增加资本公积人民币864,000.00元。- 本次行权对公司最近一期财务状 况和经营成果均不构成重大影响。 截至2025年7月28日收盘，慧智微(688512)报收于11.45元，上涨0.17%，换手率3.25%，成交量10.53万 手，成交额1.2亿元。 当日关注点 交易信息汇总 7月28日，慧智微的资金流向情况如下：- 主力资金净流出898.56万元，占总成交额7.48%；- 游资资金净 流入306.87万元，占总成交额2.55%；- 散户 ...

广州慧智微电子股份有限公司 关于2021年股票期权激励计划第二个行权期 第一次行权结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次股票期权行权的决策程序及相关信息披露 2021年3月29日，广州慧智微电子有限公司（下称"慧智有限"）做出董事会 决议，为了达到对核心员工的激励并吸引优秀人才加盟，公司董事会审议通过期权 激励方案：期权预留总额550万份，对应行权后550万元注册资本，可行权时间为公 司上市后，若公司行权前发生资本公积转增股本、净资产折股、派发股票红利、股 份拆细或缩股、配股、派息等事宜的，则预留期权份数及对应的行权后可取得注册 资本数量将相应调整；期权行权价格为4元/注册资本。 证券代码：688512 证券简称：慧智微 公告编号：2025-029 慧智有限整体变更设立股份公司后，公司按照《上海证券交易所科创板股票发 行上市审核问答》的规定，对于期权激励计划的相关事宜进行了审议，并制定了完 整的激励计划、考核管理办法等文件。 2021年9月20日，公司召开第一届董事会 ...

Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]

Meeting Overview - The second board meeting of Guangzhou Huizhi Microelectronics Co., Ltd. was held on July 10, 2025, via telecommunication, with all six directors present [2] - The meeting was chaired by Chairman Li Yang, and the procedures complied with relevant laws and company regulations [2] Resolutions Passed Use of Own Funds for Project Personnel Costs - The board approved the proposal to use self-owned funds to pay personnel costs for fundraising investment projects, with plans to later replace these funds with equivalent amounts from the fundraising account [3] - This decision aims to enhance fund utilization efficiency and does not affect the normal operation of fundraising projects or the company's daily operations [3][22] Stock Option Plan Cancellation - The board approved the cancellation of 194,000 stock options from the 2021 stock option incentive plan due to one participant's departure and the expiration of the first exercise period for others [5][41] - Specifically, 48,000 options were canceled due to one participant's departure, and 146,000 options were canceled as they were not exercised before the deadline [5][41] Voting Results - For the proposal regarding the use of self-owned funds, the voting resulted in 6 votes in favor, 0 against, and 0 abstentions [4] - For the stock option cancellation proposal, the voting resulted in 4 votes in favor, 0 against, and 2 abstentions, with two related directors abstaining from the vote [7] Fundraising and Project Details - The company raised a total of RMB 1,135.97 million from its initial public offering, with a net amount of RMB 1,028.33 million after deducting expenses [15] - The company has established a special account for the management of the raised funds, ensuring compliance with regulatory requirements [16] Rationale for Fund Usage - The decision to use self-owned funds for personnel costs is based on practical needs and regulatory compliance, ensuring that the company can meet its operational requirements without violating fundraising regulations [20][22] Impact on Daily Operations - The use of self-owned funds for project personnel costs is expected to facilitate the smooth progress of fundraising projects and improve fund utilization efficiency without harming the interests of the company or its shareholders [22][25]

Group 1 - The company held its sixth meeting of the second supervisory board, which was chaired by Zhang Dan, and the meeting complied with relevant regulations [1] - The supervisory board approved the proposal to use self-owned funds to pay personnel costs for fundraising projects, with plans to later replace these funds with equivalent amounts from the fundraising account, enhancing fund utilization efficiency [1] - The supervisory board also approved the proposal to cancel a portion of stock options from the 2021 stock option incentive plan, totaling 194,000 options, which aligns with the plan's regulations and does not harm the interests of the company or its shareholders [2][3] Group 2 - The voting results for both proposals showed unanimous support, with 3 votes in favor and no votes against or abstentions [2]

Core Viewpoint - The company, Guangzhou Huizhi Microelectronics Co., Ltd., has received approval for its initial public offering and is utilizing its own funds to pay personnel costs for fundraising projects, with plans to replace these costs with raised funds later [1][5][7]. Fundraising Overview - The company issued 54.3005 million shares at a price of 20.92 RMB per share, raising a total of 1,135.9665 million RMB, with a net amount of 1,028.3289 million RMB after deducting issuance costs of 107.6376 million RMB [1][2]. - The company has established a special account for the storage of raised funds, ensuring all funds are deposited into this account [2]. Project Adjustments - The initial fundraising plan aimed for 1,504.1878 million RMB, but adjustments were made to the allocation of funds for various projects, including the cancellation of the "Chip Testing Center Construction" project [3][4]. - The adjusted total investment for the projects is 1,246.3642 million RMB, with 1,028.3289 million RMB allocated from the raised funds [4][5]. Reasons for Using Own Funds - The company opted to use its own funds for personnel costs due to regulatory requirements regarding payment methods and the need for efficient fund management [5][6]. - The use of self-funds allows for compliance with banking regulations and ensures timely payment of salaries and related expenses [5][6]. Operational Process - The company’s human resources department prepares monthly payroll details, which are then approved internally before payment is made from the company's own funds [6]. - A formal process is in place for the subsequent replacement of these costs with raised funds, ensuring proper documentation and compliance with regulations [6]. Impact on Operations - The decision to use self-funds for personnel costs is based on the company's operational needs and is expected to enhance the efficiency of fund usage without affecting the normal implementation of fundraising projects [7][8]. - The supervisory board has approved this approach, affirming that it aligns with the company's development needs and does not harm shareholder interests [8]. Sponsor's Review - The sponsor, Huatai United Securities, has reviewed the company's decision and found it to be in accordance with relevant regulations, confirming that it will not impact the normal execution of fundraising projects [9].

Core Viewpoint - The company announced the cancellation of 194,000 stock options from the 2021 stock option incentive plan due to the departure of one incentive object and the expiration of the exercise period for another group of incentive objects [1][10]. Group 1: Stock Option Incentive Plan - The total number of stock options reserved in the 2021 stock option incentive plan is 5.5 million, with an exercise price set at 4 yuan per registered capital [1]. - The company has made adjustments to the stock option plan, including a reduction in the total number of options to no more than 22 million and a new exercise price of 1 yuan per share [3]. - The board approved the exercise of stock options for 57 incentive objects during the first exercise period, while 320,000 options were canceled due to the departure of 5 incentive objects [4][10]. Group 2: Cancellation of Stock Options - The cancellation of stock options includes 48,000 options from one departing incentive object and 146,000 options that were not exercised by another group after the expiration of their exercise period [10]. - The cancellation aligns with the regulations of the 2021 stock option incentive plan and will not materially affect the company's financial status or operational results [10][11]. - The supervisory board confirmed that the cancellation complies with the relevant provisions of the stock option incentive plan and does not harm the interests of the company or its shareholders [10].

证券代码：688512 证券简称：慧智微 公告编号：2025-027 广州慧智微电子股份有限公司 关于使用自有资金支付募投项目人员费用并以募集资金等额置换 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州慧智微电子股份有限公司（以下简称"公司"）于2025年7月10日召开第 二届董事会第七次会议和第二届监事会第六次会议，审议通过了《关于使用自有资 金支付募投项目人员费用并以募集资金等额置换的议案》，同意公司及全资子公司 作为实施主体在募集资金投资项目（以下简称"募投项目"）实施期间，根据实际 需要，先行使用自有资金支付募投项目人员费用，后续定期从募集资金专户划转等 额资金至公司自有资金账户进行置换，该部分等额置换资金视同募投项目使用资金， 上述事项无需提交公司股东会审议。公司保荐人华泰联合证券有限责任公司（以下 简称"保荐人"）对本事项出具了明确的核查意见。具体情况公告如下： 一、募集资金的基本情况 根据中国证券监督管理委员会《关于同意广州慧智微电子股份有限公司首次公 开发行股票注册的批复》（证监许可〔2023 ...

证券代码：688512 证券简称：慧智微 公告编号：2025-026 广州慧智微电子股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州慧智微电子股份有限公司（以下简称"公司"）第二届监事会第六次会议于 2025年7月10日以通讯方式召开，会议应出席监事3名，实际出席监事3名。本次会议由 监事会主席张丹主持。会议的召集、召开和表决程序符合《中华人民共和国公司法》 和《广州慧智微电子股份有限公司章程》的相关规定。经与会监事认真讨论审议，以 记名投票表决方式，审议通过如下议案： 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《广州 慧智微电子股份有限公司关于使用自有资金支付募投项目人员费用并以募集资金等额 置换的公告》（公告编号：2025-027）。 二、审议通过《关于注销2021年股票期权激励计划部分股票期权的议案》 监事会认为：根据《2021年股票期权激励计划》的规定，鉴于第一期激励对象中， 1名激励对象因离职而不再具备行权条件，公司本次注销其持 ...

一、会议召开情况 广州慧智微电子股份有限公司（以下称"公司"）第二届董事会第七次会议于 2025年7月10日以通讯方式召开。本次会议通知以电子邮件方式发出，会议应出席董 事6人，实际出席董事6人。本次会议由董事长李阳先生主持。会议的召集、召开以及 表决程序均符合《中华人民共和国公司法》和《广州慧智微电子股份有限公司章程》 的有关规定，会议合法有效。 二、会议审议情况 经与会董事认真讨论审议，以记名投票表决方式，审议通过如下议案： 1、审议通过《关于使用自有资金支付募投项目人员费用并以募集资金等额置换的 议案》 证券代码：688512 证券简称：慧智微 公告编号：2025-025 广州慧智微电子股份有限公司 第二届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2、审议通过《关于注销2021年股票期权激励计划部分股票期权的议案》 根据《2021年股票期权激励计划》的规定，鉴于第一期激励对象中，1名激励对象 因离职而不再具备行权条件，公司本次注销其持有的共计4.80万份股票期权。另外， 鉴于2021年 ...